QCG
APGE icon

Quadrant Capital Group’s Apogee Therapeutics APGE Stock Holding History

Quadrant Capital Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-94
Closed -$7.91K – 1322
2026
Q1 		$7.91K Buy
94
+3
+3% +$218 ﹤0.01% 2258
2025
Q4 		$6.87K Hold
91
– – ﹤0.01% 2297
2025
Q3 		$3.62K Buy
+91
New +$3.48K ﹤0.01% 2377

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Quadrant Capital Group's APGE Position: Q2 2026 in Review

Quadrant Capital Group sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 94 shares — an estimated $7.91K sold.

Quadrant Capital Group first reported a position in APGE in Q3 2025 and held it in 3 quarters. The position peaked at $7.91K in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Quadrant Capital Group reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 94 Apogee Therapeutics shares in Q2 2026, an estimated $7.91K.
  • Quadrant Capital Group first reported a position in Apogee Therapeutics in Q3 2025 and held it in 3 quarters.
  • Quadrant Capital Group's Apogee Therapeutics position peaked at $7.91K in Q1 2026.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.